Viking Therapeutics, Inc.
VKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001607678
In the last 90 days, Viking Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 437 institutions reported holding it in 13F filings for Q2 2026, worth $2.96B in total; no superinvestor holds it.
Superinvestors holding VKTX, Q2 2026
No superinvestor reported holding VKTX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of VKTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q4 2025
1 superinvestor holding at quarter end
Q3 2025
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q2 2025
1 superinvestor holding at quarter end
Q4 2024
0 superinvestors holding at quarter end
- Sold out
- Viking Global Investors
Q3 2024
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−46.7%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+23.7%)
Q1 2024
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−78.7%)
Q4 2023
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+12.5%)
Q3 2023
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+29.0%)
Q2 2023
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+81.3%)
Q1 2023
1 superinvestor holding at quarter end